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INTRODUCTION
Management of the gingival manifestations, clini-
cally known as desquamative gingivitis, of autoimmune 
and inflammatory mucocutaneous diseases represents a 
great challenge to oral medicine clinicians, since most 
of these diseases are of a chronic nature (1-3). While 
systemic therapy may be required for the underlying 
disease, especially in cases associated with pemphigus 
vulgaris (PV), topical corticosteroids are often the 
mainstay for the treatment of localized gingival lesions 
(4-8). Clobetasol propionate has yielded good results 
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The aim of this study was to evaluate the efficacy of a 0.05% clobetasol propionate ointment administered in trays to 22 patients with 
desquamative gingivitis in a double-blind, crossover, placebo-controlled trial. Patients received container number 1 and were instructed 
to apply the ointment 3 times a day for 2 weeks, and to reduce the application to once a day in the third week. Next, the patients were 
then instructed to discontinue the treatment for 2 weeks, and were then given container 2, used in the same way and for the same length 
of time as container 1. Regarding signs, 17 patients presented some improvement, while 5 experienced worsening with clobetasol 
propionate. With the placebo, 14 patients presented some improvement, and 8 patients presented worsening. For symptoms, there was 
complete improvement in 2 patients, partial improvement in 12, no response in 7, and worsening in 1 with clobetasol propionate. With 
the placebo, there was partial improvement in 8 patients, no response in 12 and worsening in 2. No statistically significant difference 
was found between clobetasol and placebo (p>0.05). Within the period designed to treat the gingival lesions of the patients, clobetasol 
propionate did not significantly outperform the placebo. 
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with minimal side effects when properly used (5,9-11). 
Some studies have reported good outcomes for patients 
with oral lesions treated with clobetasol propionate in a 
mouthwash (3), and in an ointment with or without an 
adherent vehicle (7-12). However, it may be difficult 
to apply the corticosteroid to the entire lesional surface 
in patients with extensive gingival lesions. It has also 
been reported that the grainy texture of the paste with 
adherent vehicle is generally disliked, often affecting 
patient compliance. In addition, physiological mouth 
movements can displace the corticosteroid from its 
initial location, precluding good control of the contact 
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time between the corticosteroid and the lesion (6,7,12). 
The use of a tray may provide a solution to this problem 
because it restrains the ointment and provides an occlu-
sive contact between the corticosteroid and the lesions 
(12,13). The present double-blind, crossover, placebo-
controlled study was carried out to evaluate the efficacy 
of clobetasol propionate administered in trays for the 
treatment of gingival manifestations of autoimmune and 
inflammatory mucocutaneous diseases.
MATERIAL AND METHODS
Patients
Twenty-two patients (17 women and 5 men; 
mean age = 50.6 ± 16.38 years; range 25-78 years) with 
chronic and symptomatic gingival lesions caused by 
autoimmune and inflammatory mucocutaneous diseases 
participated in the study. The patients were divided into 
2 groups: group 1 consisted of 5 patients, all women, 
mean age 48.2 ± 8.13 years (range 38-58 years), treated 
systemically with prednisone and/or azathioprine for 
at least 6 months for control of their mucocutaneous 
diseases. All patients in this group presented PV; the 
duration of the disease was 8.2 ± 3.42 years (range 4-11 
years). Group 2 consisted of 17 patients, 12 women, 5 
men, mean age 51.4 ± 18.25 years (range 25-78 years), 
not under systemic treatment. In this group, 3 patients 
presented PV, 5 presented mucous membrane pemphi-
goid (MMP), and 9 had oral lichen planus (OLP); the 
duration of these diseases, taken together, was 5.6 ± 
4.04 years, range 1-15 years. The characteristics of the 
patients are shown in Table 1.
The diagnosis of these diseases was made based 
on medical history and clinical examination, together 
with histopathologic (light microscopy - hematoxylin 
and eosin) and direct immunofluorescence findings of 
a biopsy specimen taken from the perilesional gingival 
mucosa. The clinical criteria for inclusion in this study 
were: presence of erythema, atrophy, vesicobullous 
areas, erosions, ulcerations and desquamative lesions, 
in multiple associations or not. Subjects were excluded 
if they presented disseminated mucocutaneous diseases 
or exacerbation of their diseases during the study period, 
or if they were taking any drugs capable of inducing 
lichenoid reactions. Blood pressure, glycemia, complete 
blood counts, and presence of candidosis were recorded 
at the start and at the end of the each protocol phase. Oral 
candidosis was diagnosed by evidence of fungal hyphae 
detected by exfoliative cytology of the gingival mucosa 
(direct exam with 10% KOH and periodic acid Schiff 
staining). The trial was approved by the local Research 
Ethics Committee and all subjects gave written informed 
consent to participate.
Drug
The drug under study was a 0.05% clobetasol pro-
pionate ointment (0.5 mg of clobetasol 17-propionate). 
The efficacy of this corticosteroid was compared to that 
of a placebo (hydroxylethyl cellulose) with the same 
physical characteristics as the corticosteroid (odorless, 
tasteless, and colorless). The ointments were prepared 
in equal containers of 30 g (containers number 1 and 2). 
The containers with randomization codes were obtained 
by Galderma Brasil Ltda, São Paulo, SP, Brazil. The code 
was not broken until completion of the crossover study. 
Study Design
After an initial periodontal treatment, a topical 
application of ointments was instituted using trays of 
Table 1. General characteristics of the patients (n=22).
Patients
Gender
Age (yrs)
Mucocutaneous diseases Duration of the 
diseases (yrs)Male Female PV MMP OLP
Group 1 (n=5) 0 5 (22.7) 38-58 (48.2 ± 8.13) 5 (22.7) 0 0 4-11 (8.2 ± 3.42)
Group 2 (n=17) 5 (22.7) 12 (54.6) 25-78 (51.4 ± 18.25) 3 (13.6) 5 (22.7) 9 (40.9) 1-15 (5.6 ± 4.04)
Total (n=22 ) 5 (22.7) 17 (77.3) 25-78 (50.6 ± 16.38) 8 (36.4) 5 (22.7) 9 (40.9) 1-15 (6.2 ± 3.98)
PV= pemphigus vulgaris; MMP= mucous membrane pemphigoid; OLP= oral lichen planus. Data are expressed as ‘number of patients (%)’.
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silicone rubber made on cast impressions. The patients 
received container number 1 and were instructed to apply 
the ointment with the tray for 20 min, 3 times daily (after 
breakfast, after lunch and after dinner), for 2 weeks. The 
frequency of use of ointment was reduced in the third 
week to once a day on alternate days. The patients were 
then instructed to discontinue the treatment for 2 weeks 
(washout period), and were given container number 2, 
to be used in the same way and at the same frequency 
and duration as container 1.
Clinical Response
Patients were examined before the trial and then 
at 2-week intervals throughout the trial. The patients’ 
clinical evaluation was recorded at each visit on their 
charts, which consisted of a diagram of the gingival mu-
cosa with 6 sites for tooth where the areas with lesions 
were marked. For signs, the response to therapy was 
defined as follows according to the percent of remission: 
complete (100%), excellent (75% to 99%), good (50% 
to 74%), poor (1% to 49%), no response, and worsened. 
Remission of symptoms was characterized as complete 
(no symptoms), partial, no response, and worsened. 
At every visit, the patients were also examined for the 
presence of side effects. Data were analyzed by Fisher’s 
exact test. Significance was set at p<0.05.
RESULTS
Data on the clinical response of patients in each 
phase of this study are summarized in Tables 2 and 
3. With respect to the evaluation of signs, 17 patients 
(77.2%) presented some improvement (Fig. 1), while 5 
(22.7%) presented worsening with the use of clobetasol 
propionate. With the placebo, 14 patients (63.6%) pre-
sented some improvement, while 8 patients (36.4%) had 
worsening of signs (Table 2). For symptoms, complete 
improvement was observed in 2 patients (9.1%), partial 
improvement in 12 (54.5%), no response in 7 (31.8%) 
and worsening in 1 during the clobetasol phase. Dur-
ing the placebo phase, 8 patients (36.4%) had partial 
improvement, 12 (54.5%) no response and 2 (9.1%) 
showed worsening (Table 3). 
Despite a tendency of the patients to respond 
slightly better to clobetasol in terms of improvement 
of signs and symptoms of their gingival lesions, no 
statistically significant difference was found between 
the results obtained with clobetasol propionate and the 
placebo (p>0.05). With respect to side effects, only 2 
patients (9.1%) developed candidosis during the use of 
clobetasol propionate. These 2 patients were additionally 
treated with an antifungal (Nistatin) in oral suspension 
for 3 weeks, and a further retest for Candida sp was 
negative. No other side effects were observed in the 
patients of this study.
DISCUSSION
By comparing the severity of lesions at baseline 
with their outcome at the end of the trial, it was found 
that patients in the clobetasol phase showed a slightly 
better improvement of clinical signs and symptoms 
compared with those in the placebo phase, although the 
Figure 1. Clinical photographs of patient illustrating the response 
to the treatment . A = Erosive lesions in the marginal gingiva of a 
patient with pemphigus vulgaris. B = Partial remission following 
15 days of treatment with clobetasol propionate.
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Table 2. Clinical response of signs of patients treated with clobetasol propionate and placebo.
Patients
Response of signs
Complete Excellent Good Poor No response Worse Total
Group 1 (n=5)
Clobetasol 0 0 0 4 (80) 0 1 (20) 5 (100)
Placebo 0 0 0 4 (80) 0 1 (20) 5 (100)
p values 1.00 1.00 1.00 0.65 1.00 0.75 ---
Group 2 (n=17)
Clobetasol 0 1 (5.9) 2 (11.8) 10 (58.8) 0 4 (23.5) 17 (100)
Placebo 0 2 (11.8) 0 8 (47) 0 7 (41.2) 17 (100)
p values 1.00 0.50 0.24 0.36 1.00 0.23 ---
All patients (n=22)
Clobetasol 0 1 (4.5) 2 (9.1) 14 (63.6) 0 5 (22.7) 22 (100)*
Placebo 0 2 (9.1) 0 12 (54.5) 0 8 (36.4) 22 (100)*
p values 1 0.49 0.24 0.37 1.00 0.25 ---
Data are expressed as ‘number of patients (%)’; * ns - nonsignificant (Fisher’s exact test; p>0.05).
Table 3. Clinical response of symptoms of patients treated with clobetasol propionate and placebo.
Patients
Response of symptoms 
Complete Partial No response Worse Total
Group 1 (n=5)
Clobetasol 0 3 (60) 1 (20) 1 (20) 5 (100)
Placebo 0 1 (20) 4 (80) 0 5 (100)
p values 1.00 0.26 0.10 0.50 ---
Group 2 (n=17)
Clobetasol 2 (11.8) 9 (52.9) 6 (35.2) 0 17 (100)
Placebo 0 7 (41.2) 8 (47) 2 (11.8) 17 (100)
p values 0.24 0.36 0.36 0.24 ---
All patients (n=22)
Clobetasol 2 (9.1) 12 (54.5) 7 (31.8) 1 (4.5) 22 (100)*
Placebo 0 8 (36.4) 12 (54.5) 2 (9.1) 22 (100)*
p values 0.24 0.18 0.11 0.49 ---
Data are expressed as ‘number of patients (%)’; * ns - nonsignificant (Fisher’s exact test; p>0.05).
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difference did not reach statistical significance (p>0.05). 
The failure of the corticosteroid to significantly out-
perform the placebo indicates that its vasoconstrictive, 
anti-inflammatory and immunosuppressive properties 
are not sufficient to suppress the immunologic and 
inflammatory mechanism involved in the development 
of the studied lesions. That both clobetasol propionate 
and the placebo ointment proved to be effective to some 
degree could be due to a protective and lubricating 
function of the ointment in conjunction with the use 
of trays. The occlusion produced by use of trays can 
have favored the protection of gingival tissues against 
functional movements of mouth.
Some double-blind studies showed the safety of 
topical clobetasol propionate in the treatment of oral 
vesiculo-erosive lesions (5,6,9,10,14). Clobetasol in 
orabase paste administered in trays 3 times daily around 
2 weeks of treatment provided good outcomes in patients 
with severe erosive gingival lesions (11-13). On the 
other hand, clobetasol ointment used for 4 weeks in DG 
treatment had previously been found to be significantly 
less effective when it was compared with other drugs, 
such as tacrolimus (15).
It has been recognized that either systemic or 
topical corticotherapy may bring about serious side 
effects, such as increased susceptibility to infections, 
hypertension, hyperglycemia, fluid retention, and 
adrenal cortex suppression (1,6,16,17). With regard 
to topical therapy, the risk of side effects is increased 
when a high-potency corticosteroid is used in combina-
tion with occlusive techniques (17). Although only one 
study (3) has reported significant side effects with the 
use of topical high-potency corticosteroids in ulcerative 
and/or erosive oral lesions, there is a consensus among 
authors that patients under this type of treatment should 
be monitored carefully (12,16,17). The patients applied 
the corticosteroid to their gingival lesions for a period 
of 3 weeks. This length of time was sufficient to evalu-
ate side effects, since some studies have indicated that 
adrenal suppression may occur as early as 24 h after 
initiating topical corticotherapy when used on the skin 
(16,18,19). The most common side effect of topical cor-
ticotherapy is candidosis (17,20). In the present study, 
only 2 patients (11.8%) developed candidosis after the 
use of clobetasol propionate. These patients were treated 
with a topical antifungal agent without interrupting the 
use of clobetasol. No other side effect was observed in 
the patients under study.
Topical corticosteroids, used as described in this 
paper, are usually safe and can be of some efficacy as 
adjunct therapy in combination with systemic treatment 
in patients with oral and skin lesions, or in the treatment 
of patients with gingival lesions alone. Although some of 
our patients did not show improvement of their gingival 
lesions while using clobetasol propionate, this may have 
been due to the limited sample size and the relatively 
short period of treatment. However, this shorter period 
does reduce the risk of side effects. A risk/benefit analysis 
should be undertaken when considering an increase in 
the dosage of any medication. 
RESUMO
O objetivo deste estudo foi avaliar a eficácia do propionato de 
clobetasol a 0,05% administrada com moldeiras em 22 pacientes 
com gengivite descamativa por meio de estudo duplo-cego, cru-
zado, placebo-controlado. Pacientes receberam bisnaga número 
1 e foram instruídos a aplicar a pomada 3 vezes ao dia por um 
período de 2 semanas, e reduzir a aplicação para 1 vez ao dia 
na terceira semana. Os pacientes foram instruídos a suspender 
o tratamento por 2 semanas, e então receberam a bisnaga 2, 
usando-a da mesma maneira que o container 1. Com relação aos 
sinais, 17 pacientes apresentaram alguma melhora, enquanto 
5 apresentaram piora com o propionato de clobetasol. Com o 
uso do placebo, 14 pacientes apresentaram alguma melhora, 
e 8 pacientes apresentaram piora do seu quadro clínico. Com 
relação aos sintomas, houve completa melhora em 2 pacientes, 
melhora parcial em 12, ausência de resposta em 7, e piora em 
1 pacientes durante o uso do propionato de clobetasol. Com o 
uso do placebo, houve melhora parcial em 8 pacientes, ausência 
de resposta em 12 e piora dos sintomas em 2 pacientes. Não foi 
verificada diferença estatisticamente significante em nenhum dos 
parâmetros entre o uso do clobetasol e placebo; p>0,05. Baseado 
no protocolo utilizado neste grupo de pacientes, o propionato 
de clobetasol não demonstrou efetividade significante quando 
comparado ao placebo. 
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